Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 5/20 | 0.68 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.68 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.68 |
| ▸ | F10 | P00742 | 2/20 | 0.61 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.61 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.55 |
| ▸ | F2 | P00734 | 5/20 | 0.52 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.52 |
| ▸ | PLAU | P00749 | 2/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | C1S | P09871 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | MASP2 | O00187 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10622182 | 0.85 | PRSS1 (0.61) | PRSS1PRSS3PRSS2F10LOXL2 | |
| SCHEMBL12965227 | 0.84 | PRSS1 (0.59) | PRSS1PRSS3PRSS2F10LOXL2 | |
| SCHEMBL7815090 | 0.82 | F10 (0.68) | PRSS1PRSS3PRSS2F10LOXL2 | |
| Hydrochloric Acid SCHEMBL22401635 | 0.82 | PRSS1 (0.76) | PRSS1F10ST14F2PLAU | |
| SCHEMBL1587086 | 0.81 | PRSS1 (1.00) | PRSS1PRSS3PRSS2F10LOXL2 | |
| Hydrochloric Acid SCHEMBL8173513 | 0.80 | F10 (0.65) | PRSS1PRSS3PRSS2F10LOXL2 | |
| SCHEMBL8420366 | 0.80 | PRSS1 (0.59) | PRSS1PRSS3PRSS2F10LOXL2 | |
| Hydrochloric Acid SCHEMBL10925118 | 0.78 | LOXL2 (0.83) | PRSS1PRSS3PRSS2F10LOXL2 | |
| SCHEMBL7818542 | 0.78 | F10 (0.63) | PRSS1PRSS3PRSS2F10LOXL2 | |
| Hydrochloric Acid SCHEMBL10342835 | 0.78 | PRSS1 (0.57) | PRSS1PRSS3PRSS2F10LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4494698-A2 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2025-01-22 | — | — | EP | disclosed |
| EP-3661922-B1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-23 | — | — | EP | disclosed |
| US-20240199602-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-20 | — | — | US | disclosed |
| US-11905285-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-20 | — | — | US | disclosed |
| US-20220056028-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-02-24 | — | — | US | disclosed |
| US-11168083-B2 | Inhibitors of Plasma Kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-09 | — | — | US | disclosed |
| US-11168083-B2 | Inhibitors of Plasma Kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-09 | — | — | US | disclosed |
| US-20200239463-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | DYAX CORP. (US) | 2020-07-30 | — | — | US | disclosed |
| US-20200239463-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | DYAX CORP. (US) | 2020-07-30 | — | — | US | disclosed |
| EP-3661922-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | Dyax Corp. (US) | 2020-06-10 | — | — | EP | disclosed |
| WO-2019028362-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | DYAX CORP. (US) | 2019-02-07 | — | — | WO | disclosed |
| WO-2019028362-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | DYAX CORP. (US) | 2019-02-07 | — | — | WO | disclosed |
| WO-2019010192-A1 | FUNGICIDAL OXADIAZOLES | FMC CORPORATION (US) | 2019-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199602-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | PRSS1 21/4885PRSS3 52/4885PRSS2 64/4885 |
| US-11168083-B2 | Inhibitors of Plasma Kallikrein and uses thereof | KLKB1, KLK1, KLK5 | PRSS1 21/4885PRSS3 52/4885PRSS2 64/4885 |
| US-20200239463-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | PRSS1 21/4885PRSS3 52/4885PRSS2 64/4885 |
| US-20220056028-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | PRSS1 21/4885PRSS3 52/4885PRSS2 64/4885 |
| US-11905285-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | PRSS1 21/4885PRSS3 52/4885PRSS2 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.